TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24314209

Group type: EXPERIMENTAL
Intervention: Metabolomic based prototype test
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Proteomic based prototype test
Number of subjects: 5000
Study: 24314292

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RARα antagonist Ro415253
Number of subjects: 0
Study: 24314307

Group type: EXPERIMENTAL
Intervention: S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: S-1 combined with docetaxel (SD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 49
Study: 24314346

Group type: EXPERIMENTAL
Intervention: G-allele carriers
Number of subjects: 81

Group type: COMPARATOR
Intervention: AA-homozygotes
Number of subjects: 81
Study: 24315482

Group type: EXPERIMENTAL
Intervention: Direct DDMFs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reversed DDMFs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 24315509

Group type: EXPERIMENTAL
Intervention: % trunk fat
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: % leg fat
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: % arm fat
Number of subjects: 391
Study: 24315990

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor antagonist exendin (9-39) (Ex-9)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 24
Study: 24316314

Group type: EXPERIMENTAL
Intervention: Fermented Papaya Preparation (FPP) 6g/day for 14 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: In vitro free radical scavenging activities of FPP
Number of subjects: 0
Study: 24317406

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (3 weeks of text messages)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 31
Study: 24318487

Group type: EXPERIMENTAL
Intervention: Body composition measured by dual energy X-ray absorptiometry
Number of subjects: 776
Study: 24319018

Group type: EXPERIMENTAL
Intervention: Prechemotherapy assessment of serum AMH
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Detectable serum AMH concentration at chemotherapy initiation
Number of subjects: 27
Study: 24319462

Group type: EXPERIMENTAL
Intervention: Arthrocentesis using saline and sodium hyaluronate injections
Number of subjects: 30
Study: 24319489

Group type: EXPERIMENTAL
Intervention: Caraway extract (CE) 30 mL/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 24320967

Group type: EXPERIMENTAL
Intervention: Oral mucosal potentially malignant diseases (PMD) management
Number of subjects: 0
Study: 24321536

Group type: EXPERIMENTAL
Intervention: Pubertal group (actively progressing through puberty, n = 16)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Peripubertal group (n = 25)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pubertal group (actively progressing through puberty)
Number of subjects: 41
Study: 24321701

Group type: EXPERIMENTAL
Intervention: The Food Friends nutrition intervention (12 weeks) and physical activity intervention (18 weeks) during preschool.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (3 sites)
Number of subjects: 0
Study: 24321742

Group type: EXPERIMENTAL
Intervention: Soda consumption
Number of subjects: 128
Study: 24321746

Group type: EXPERIMENTAL
Intervention: Intravenous administration of third party bone marrow-derived mesenchymal stromal cells (MSC)
Number of subjects: 40
Study: 24321803

Group type: EXPERIMENTAL
Intervention: mMRC scale
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: SGRQ
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Lung function only
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Previous exacerbation history only
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Both lung function and previous exacerbation history
Number of subjects: 4484
Study: 24322398

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 5640

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 5640

Group type: COMPARATOR
Intervention: β Blockers
Number of subjects: 5640

Group type: COMPARATOR
Intervention: Calcium Channel Blockers
Number of subjects: 5640
Study: 24322571

Group type: EXPERIMENTAL
Intervention: ANI measured immediately before tracheal extubation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ANI threshold <50
Number of subjects: 200
Study: 24323026

Group type: EXPERIMENTAL
Intervention: Neratinib (200 mg) + Temsirolimus (25 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neratinib (160 mg) + Temsirolimus (50 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neratinib + Temsirolimus
Number of subjects: 60
Study: 24323468

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 gram infused over 30 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ertapenem dosing regimens: 500 mg once daily, 750 mg once daily, 500 mg twice daily, and 1,000 mg once daily
Number of subjects: 8
Study: 24323708

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) in the subacute phase (2-4 weeks after aSAH)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation of functional outcomes in the chronic phase (1 year after aSAH)
Number of subjects: 108
Study: 24323994

Group type: EXPERIMENTAL
Intervention: Assault-injured youth
Number of subjects: 925

Group type: COMPARATOR
Intervention: Comparison youth
Number of subjects: 925
Study: 24324590

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg, every other day for 12 weeks
Number of subjects: 14
Study: 24325689

Group type: EXPERIMENTAL
Intervention: 4-F-compatible materials (self-expanding nitinol stents: Astron Pulsar or Pulsar-18 stent)
Number of subjects: 120
Study: 24325691

Group type: EXPERIMENTAL
Intervention: EPIC self-expanding nitinol stent
Number of subjects: 100
Study: 24326155

Group type: EXPERIMENTAL
Intervention: Full conditioning (FC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (standard laparoscopy)
Number of subjects: 44
Study: 24326304

Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation in participants aged 50 years or older
Number of subjects: 1025
Study: 24327334

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus everolimus
Number of subjects: 31
Study: 24328387

Group type: EXPERIMENTAL
Intervention: LAP-BAND AP (LBAP) system
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (patients without OSA at baseline)
Number of subjects: 57
Study: 24328415

Group type: EXPERIMENTAL
Intervention: LAP-BAND AP laparoscopic adjustable gastric band (LAGB)
Number of subjects: 1620
Study: 24328727

Group type: EXPERIMENTAL
Intervention: Low-fat diet (28% fat, 12% MUFA)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Mediterranean diet (35% fat, 22% MUFA)
Number of subjects: 475
Study: 24329107

Group type: EXPERIMENTAL
Intervention: Autologous epidermal sheets generated from ex vivo gene-corrected keratinocyte stem cells
Number of subjects: 0
Study: 24329122

Group type: EXPERIMENTAL
Intervention: Dobutamine stress
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (matched controls)
Number of subjects: 19
Study: 24329524

Group type: EXPERIMENTAL
Intervention: Continuing metformin
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: Continuing thiazolidinediones
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: Continuing DPP-IV inhibitors
Number of subjects: 17374

Group type: COMPARATOR
Intervention: Discontinuing sulphonylureas
Number of subjects: 17374

Group type: COMPARATOR
Intervention: Discontinuing glinides
Number of subjects: 17374

Group type: COMPARATOR
Intervention: Discontinuing thiazolidinediones
Number of subjects: 17374

Group type: COMPARATOR
Intervention: Discontinuing DPP-IV inhibitors
Number of subjects: 17374

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 17374
Study: 24329937

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a/ribavirin
Number of subjects: 2109
Study: 24330256

Group type: EXPERIMENTAL
Intervention: Low gut microbiota diversity during the first month of life
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low gut microbiota diversity during the first week of life
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IgE-associated eczema in infancy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Gut microbiota diversity at 12 months of age
Number of subjects: 47

Group type: COMPARATOR
Intervention: Gut microbiota diversity
Number of subjects: 47
Study: 24330333

Group type: EXPERIMENTAL
Intervention: Complicated AHA-LT VI plaques in cryptogenic stroke patients ipsilateral to the ischemic stroke
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: AHA-LT VI plaques
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: New ischemic lesions on cerebral MRI (including clinically silent lesions)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Specific AHA-LT VI plaque features
Number of subjects: 300
Study: 24330446

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 33
Study: 24330454

Group type: EXPERIMENTAL
Intervention: Western dietary pattern
Number of subjects: 210

Group type: COMPARATOR
Intervention: Prudent dietary pattern
Number of subjects: 210
Study: 24330470

Group type: EXPERIMENTAL
Intervention: PCRM-CI intervention group
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 149
Study: 24330670

Group type: EXPERIMENTAL
Intervention: Oral ATP supplementation (400 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24330868

Group type: EXPERIMENTAL
Intervention: Lurasidone (40-120 mg/day)
Number of subjects: 148
Study: 24331202

Group type: EXPERIMENTAL
Intervention: NIDCM patients (n=13)
Number of subjects: 13
Study: 24331859

Group type: EXPERIMENTAL
Intervention: Recent reproductive coercion (RC)
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Exposure to recent RC
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Exposure to recent RC with history of IPV
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: History of IPV without recent RC
Number of subjects: 3539
Study: 24332189

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: High-Density Lipoprotein (HDL)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Glutathione-S-transferase α3
Number of subjects: 87
Study: 24332215

Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Number of subjects: 7
Study: 24332241

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Number of subjects: 31
Study: 24332409

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 54
Study: 24332418

Group type: EXPERIMENTAL
Intervention: Computed tomography-derived fractional flow reserve (FFRct) before intervention
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Computed tomography-derived fractional flow reserve (FFRct) after virtual stenting
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of FFRct to predict ischemia (FFR ≤ 0.8) prior to stenting
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of FFRct to predict ischemia (FFR ≤ 0.8) after stenting
Number of subjects: 44
Study: 24332512

Group type: EXPERIMENTAL
Intervention: Pidilizumab (3 mg/kg IV every 4 weeks for four infusions, plus eight optional infusions every 4 weeks) + Rituximab (375 mg/m² IV weekly for 4 weeks starting 17 days after first pidilizumab infusion)
Number of subjects: 32
Study: 24333321

Group type: EXPERIMENTAL
Intervention: Strategies to increase fluid intake in residential care homes, including identifying and overcoming barriers to drinking.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 24333512

Group type: EXPERIMENTAL
Intervention: Screening colonoscopies
Number of subjects: 7215
Study: 24334153

Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nosocomial RVGE
Number of subjects: 0
Study: 24334158

Group type: EXPERIMENTAL
Intervention: Prophylaxis with low-molecular-weight heparin or factor Xa-inhibitors only during hospitalisation when LOS ≤5 days.
Number of subjects: 4924
Study: 24334159

Group type: EXPERIMENTAL
Intervention: Combined continence education and self-management (17 clusters, 61 women)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Continence education (20 clusters, 64 women)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Evidence-based self-management (17 clusters, 70 women)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control intervention (educational workshop on memory loss, polypharmacy and osteoporosis) (17 clusters, 64 women)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Combined intervention vs Control
Number of subjects: 259
Study: 24334175

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 8 weeks in T1D-H group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg QD for 8 weeks in T1D-N group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Empagliflozin in both groups
Number of subjects: 40
Study: 24334294

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide + Anagrelide
Number of subjects: 347
Study: 24335103

Group type: EXPERIMENTAL
Intervention: Lenalidomide monotherapy
Number of subjects: 32
Study: 24335156

Group type: EXPERIMENTAL
Intervention: Whole-leg X-ray
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clinical examination using the Mikulicz line
Number of subjects: 31
Study: 24335249

Group type: EXPERIMENTAL
Intervention: Recombinant human antithrombin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic drug-monitoring scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dosing model
Number of subjects: 0
Study: 24335413

Group type: EXPERIMENTAL
Intervention: Head rotation more than 45° (left or right) during surgery
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Head lift from head support
Number of subjects: 52
Study: 24335442

Group type: EXPERIMENTAL
Intervention: Acute care emergency surgery
Number of subjects: 6098
Study: 24335498

Group type: EXPERIMENTAL
Intervention: Cohesin complex mutations
Number of subjects: 389
Study: 24335595

Group type: EXPERIMENTAL
Intervention: Cetuximab and radiotherapy (cetux-RT) added to perioperative chemotherapy (ECX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Perioperative chemotherapy (ECX)
Number of subjects: 12
Study: 24335630

Group type: EXPERIMENTAL
Intervention: Nonoperative treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Successful union
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nonunion patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neck Disability Index and SF-36 version 2
Number of subjects: 50
Study: 24335884

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 803
Study: 24337621

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1, 80 mg on days 2-3), Ramosetron (0.6 mg on day 1), Dexamethasone (20 mg on day 1)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Aprepitant, Ramosetron, Dexamethasone
Number of subjects: 89
Study: 24338498

Group type: EXPERIMENTAL
Intervention: Targeted therapies (tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard evaluation criteria based on tumor size (RECIST)
Number of subjects: 32
Study: 24339028

Group type: EXPERIMENTAL
Intervention: Volasertib (300 mg on day 1 every 3 weeks, escalated to 350 mg in cycle 2 if tolerated)
Number of subjects: 50
Study: 24341332

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Standard therapy (enoxaparin overlapping with and followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 439

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 439
Study: 24342300

Group type: EXPERIMENTAL
Intervention: pemetrexed (500 mg/m2 IV)
Number of subjects: 154

Group type: COMPARATOR
Intervention: docetaxel (75 mg/m2 IV)
Number of subjects: 154
Study: 24342407

Group type: EXPERIMENTAL
Intervention: Non-selective endothelin receptor antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24343893

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (900 mg once weekly for 3 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (600 mg once daily for 10 scheduled doses)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Raltegravir alone (400 mg every 12 h for 4 days)
Number of subjects: 21
Study: 24344045

Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 0
Study: 24344220

Group type: EXPERIMENTAL
Intervention: LMP-CTLs as adjuvant therapy
Number of subjects: 50
Study: 24345357

Group type: EXPERIMENTAL
Intervention: Pantera Lux paclitaxel-coated balloon
Number of subjects: 1064
Study: 24345402

Group type: EXPERIMENTAL
Intervention: NHDL-C (discordant)
Number of subjects: 27533

Group type: EXPERIMENTAL
Intervention: apoB (discordant)
Number of subjects: 27533

Group type: EXPERIMENTAL
Intervention: LDL-P (discordant)
Number of subjects: 27533
Study: 24345751

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg per day
Number of subjects: 570
Study: 24345753

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 43
Study: 24347141

Group type: EXPERIMENTAL
Intervention: Propranolol initiation in inpatient setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol initiation in outpatient setting
Number of subjects: 0
Study: 24347462

Group type: EXPERIMENTAL
Intervention: ABT-751 (200 mg/m² PO daily × 7 days every 21 days)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ABT-751
Number of subjects: 91

Group type: COMPARATOR
Intervention: Historical control group (n = 136)
Number of subjects: 91
Study: 24347518

Group type: EXPERIMENTAL
Intervention: PAM50 Risk of Recurrence score
Number of subjects: 1478
Study: 24349052

Group type: EXPERIMENTAL
Intervention: Ataluren 4, 4, 8 mg/kg three times per day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ataluren 10, 10, 20 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ataluren 20, 20, 40 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ataluren (all doses)
Number of subjects: 38
Study: 24349086

Group type: EXPERIMENTAL
Intervention: 2 g per day of ALA
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1622
Study: 24349334

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily for 7 days
Number of subjects: 40
Study: 24349470

Group type: EXPERIMENTAL
Intervention: PRS-050 at 0.1 mg/kg to 10 mg/kg by IV
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PRS-050 infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PRS-050
Number of subjects: 26
Study: 24350732

Group type: EXPERIMENTAL
Intervention: Usual-care + Sugarsquare intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 62
Study: 24351073

Group type: EXPERIMENTAL
Intervention: Serum CXCL-9 levels in antibody-positive women with a history of abortions
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Serum CXCL-11 levels in antibody-positive women with a history of abortions
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Serum CXCL-9 levels in patients with AIT without RSA
Number of subjects: 105

Group type: COMPARATOR
Intervention: CXCL-9 and -11 levels in subjects with a history of RSA
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analyses for abortions
Number of subjects: 105
Study: 24351336

Group type: EXPERIMENTAL
Intervention: lenalidomide monotherapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: lenalidomide/cetuximab combination treatment
Number of subjects: 1
Study: 24351518

Group type: EXPERIMENTAL
Intervention: NSAID therapy
Number of subjects: 4144
Study: 24351877

Group type: EXPERIMENTAL
Intervention: Higher Mediterranean diet score
Number of subjects: 93122

Group type: EXPERIMENTAL
Intervention: Higher DASH diet score
Number of subjects: 93122
Study: 24351882

Group type: EXPERIMENTAL
Intervention: Real-time assessment of pulmonary vein disconnection using the Achieve(®) catheter (AC) in standard position
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Real-time assessment of pulmonary vein disconnection using the Achieve(®) catheter (AC) after moving to a more proximal position
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Real-time assessment of pulmonary vein disconnection using supplemental systematic pacing manoeuvres
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall real-time assessment of pulmonary vein disconnection
Number of subjects: 34
Study: 24351885

Group type: EXPERIMENTAL
Intervention: Persistent AF
Number of subjects: 702

Group type: COMPARATOR
Intervention: Paroxysmal AF
Number of subjects: 702
Study: 24351969

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 1
Study: 24352251

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day as maintenance therapy after cCRT
Number of subjects: 66
Study: 24352795

Group type: EXPERIMENTAL
Intervention: MLN8237 (alisertib) ECT 50 mg BID for 7 days in 21-day cycles
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MLN8237 (alisertib) ECT
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MLN8237 (alisertib)
Number of subjects: 58
Study: 24353258

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion reserve (MPR)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Exercise testing
Number of subjects: 170

Group type: COMPARATOR
Intervention: Brain natriuretic peptide (BNP)
Number of subjects: 170
Study: 24354947

Group type: EXPERIMENTAL
Intervention: Observational data collection on patient characteristics, therapeutic interventions, psychosocial parameters, quality of life of caregiver and patient, caregiver burden, and health economic parameters.
Number of subjects: 300
Study: 24355090

Group type: EXPERIMENTAL
Intervention: Two-dose schedule (M 0-6)
Number of subjects: 974

Group type: COMPARATOR
Intervention: Three-dose schedule (M 0-1-6)
Number of subjects: 974
Study: 24355487

Group type: EXPERIMENTAL
Intervention: Anastrozole therapy
Number of subjects: 1916
Study: 24355823

Group type: EXPERIMENTAL
Intervention: Flicker-defined form (FDF) perimetry
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard automated perimetry (SAP)
Number of subjects: 206